

Remarks

Applicants elect Group I (claims 1-9, 11, 12, and 14) drawn to a transgenic plant transformed with a dermaseptin nucleic acid, and SEQ ID NOS: 3 (amino acid sequence; as well as SEQ ID NO: 28 which includes SEQ ID NO: 3) and SEQ ID NO: 27 (nucleic acid sequence), with traverse.

Claims 1-15 were pending. Claims 1-3, 5, 6-8 and 12 have been amended. Claims 10, 11, 13, and 15 have been withdrawn without prejudice to prosecution in a divisional application. Therefore, claims 1-20 are now pending.

The specification was amended to correct a typographical error in a SEQ ID NO.

Claims 1-3, 6-8, 12 and 14 were amended in view of the election.

Claim 5 was amended to include reference to sequence identifiers.

Claim 11 was amended to correct the dependency.

Support for the new claims can be found throughout the application; for example:

Claim 16: page 13, lines 22-25;

Claim 17: page 27, lines 4-5;

Claim 18: page 8, lines 24-38;

Claim 19: page 18, lines 23-25;


Claim 20: page 3, lines 23-24.

Applicants thank Examiner Kruse for discussing the restriction with Applicants' representative Sheree Lynn Rybak, Ph.D. on November 12, 2003, and indicating that both SEQ ID NOS: 3 and 28 could be examined in the same application because SEQ ID NO: 3 is a subsequence of SEQ ID NO: 28 (SEQ ID NO: 28 has a 5 amino acid N-terminal extension).

If there are any questions about this amendment, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446